BRPI0412194A - composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida - Google Patents

composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida

Info

Publication number
BRPI0412194A
BRPI0412194A BRPI0412194-5A BRPI0412194A BRPI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A BR PI0412194 A BRPI0412194 A BR PI0412194A
Authority
BR
Brazil
Prior art keywords
dog
cird
antibody
composition
immune response
Prior art date
Application number
BRPI0412194-5A
Other languages
English (en)
Inventor
John Brownlie
Victoria Jane Chalker
Kerstin Erles
Original Assignee
Royal Veterinary College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Veterinary College filed Critical Royal Veterinary College
Publication of BRPI0412194A publication Critical patent/BRPI0412194A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçãO, MéTODOS PARA VACINAR UM CãO CONTRA DOENçA RESPIRATóRIA INFECCIOSA CANINA, PARA TRATAR CIRD EM UM CãO, PARA ESTIMULAR UMA RESPOSTA IMUNE, PARA PREPARAR E OBTER UM ANTICORPO, PARA IMUNIZAR PASSIVAMENTE UM CãO CONTRA CIRD, E PARA DETERMINAR SE UM CãO FOI EXPOSTO A UMA ESPéCIE DE CHLAMYDOPHILA ASSOCIADA COM CIRD, OU SE UM CãO APRESENTA, OU é SUSCETìVEL A CIRD, USOS DE QUALQUER UM OU MAIS AGENTES, E DE ANTICORPOS, KIT DE PARTES PARA UMA COMPOSIçãO DE VACINA, ANTICORPO, ENSAIO IMUNOSSORVENTE, E, SUBSTRATO DE FASE SOLIDA". Uma composição de vacina para vacinar cães compreendendo qualquer um ou mais de (a) um agente capaz de suscitar uma resposta imunológica contra Streptococcus equi subespécie zooepidedemicus em um cão. (b) um agente capaz de suscitar uma resposta imunológica contra Mycoplasma cynos em um cão, e (c) um agente capaz de suscitar uma resposta imunológica contra um Chlamydophila em um cão.
BRPI0412194-5A 2003-07-01 2004-07-01 composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida BRPI0412194A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315323.6A GB0315323D0 (en) 2003-07-01 2003-07-01 Vaccine composition
PCT/GB2004/002865 WO2005002618A1 (en) 2003-07-01 2004-07-01 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird)

Publications (1)

Publication Number Publication Date
BRPI0412194A true BRPI0412194A (pt) 2006-08-22

Family

ID=27676393

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412194-5A BRPI0412194A (pt) 2003-07-01 2004-07-01 composição, métodos para vacinar um cão contra doença respiratória infecciosa canina, para tratar cird em um cão, para estimular uma resposta imune, para preparar e obter um anticorpo, para imunizar passivamente um cão contra cird , e para determinar se um cão foi exposto a uma espécie de chlamydophila associada com cird, ou se um cão apresenta, ou é suscetìvel a cird, usos de qualquer um ou mais agentes, e de anticorpos, kit de partes para uma composição de vacina, anticorpo, ensaio imunossorvente, e, substrato de fase sólida

Country Status (20)

Country Link
US (3) US8329194B2 (pt)
EP (2) EP1638599B1 (pt)
JP (1) JP5698890B2 (pt)
KR (1) KR20060106809A (pt)
CN (1) CN1845754A (pt)
AT (1) ATE442857T1 (pt)
AU (1) AU2004253344B2 (pt)
BR (1) BRPI0412194A (pt)
CA (1) CA2530797C (pt)
DE (1) DE602004023196D1 (pt)
DK (1) DK2050463T3 (pt)
ES (2) ES2356396T3 (pt)
GB (1) GB0315323D0 (pt)
MX (1) MXPA06000278A (pt)
NO (1) NO20056207L (pt)
NZ (1) NZ544453A (pt)
PT (1) PT2050463E (pt)
RU (1) RU2006102863A (pt)
WO (1) WO2005002618A1 (pt)
ZA (1) ZA200600918B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN100388952C (zh) * 2006-04-25 2008-05-21 范红结 一种链球菌重组亚单位疫苗及其制备方法
UA99719C2 (ru) * 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
BR112012022680B1 (pt) * 2010-03-10 2021-03-02 Intervet International B.V uso de uma vacina inativada contra vírus da influenza canina
CN103596588B (zh) * 2011-02-04 2016-02-03 佐蒂斯有限责任公司 用于犬呼吸道疾病综合征的组合物
US20130302369A1 (en) 2011-02-04 2013-11-14 Omar Yousif Abdelmagid Immunogenic Bordetella Bronchiseptica Compositions
MX363510B (es) 2012-05-31 2019-03-26 Zoetis Llc Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.
CN111499702B (zh) * 2020-05-07 2021-04-06 山东畜牧兽医职业学院 一种马链球菌兽疫亚种的检测试剂盒及检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
GB8426468D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
GB8517895D0 (en) 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US4944972A (en) * 1987-12-31 1990-07-31 American National Can Company Coextrusion apparatus, methods, and related films and packages
US5672350A (en) * 1989-08-22 1997-09-30 Veterinary Infectious Disease Organization Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
US5583014A (en) * 1990-07-03 1996-12-10 Bayer Corporation Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
US6372224B1 (en) * 1990-11-14 2002-04-16 Pfizer Inc. Canine coronavirus S gene and uses therefor
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
ATE256746T1 (de) 1991-04-25 2004-01-15 Akzo Nobel Nv Subeinheits-impfstoff gegen hundecoronavirus
DE4134297A1 (de) * 1991-10-17 1993-04-22 Behringwerke Ag Monoclonale antikoerper gegen mycoplasma pneumoniae, diese produzierende hybridome, verfahren zu deren herstellung sowie deren verwendung
DE69332375T2 (de) 1992-05-08 2003-02-13 Pfizer Hundecoronavirus s gen und verwendung davon
US5750112A (en) * 1993-02-26 1998-05-12 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
ES2183867T3 (es) * 1994-02-18 2003-04-01 Solidose L L C Inoculacion de animales con materiales biologicos secados en peletes.
DE69633233T2 (de) * 1995-06-12 2005-08-11 Kansas State University Research Foundation, Manhattan Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
EP0934410A1 (en) 1996-10-11 1999-08-11 Human Genome Sciences, Inc. Brain-associated inhibitor of tissue-type plasminogen activator
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
WO1999025838A1 (en) 1997-11-14 1999-05-27 University Of Georgia Research Foundation, Inc. Compositions and methods to prevent turkey enteritis
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE60007668T2 (de) 1999-01-26 2004-12-02 Akzo Nobel N.V. Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes
US20010048927A1 (en) * 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
GB0217434D0 (en) 2002-07-27 2002-09-04 Royal Vetinary College Biological material
CA2501621C (en) 2002-10-11 2012-01-24 Bengt Guss Immunization of non-human mammals against streptococcus equi
US7793433B2 (en) * 2006-07-14 2010-09-14 Footbalance System Oy Individually formed footwear and a related method

Also Published As

Publication number Publication date
NO20056207L (no) 2006-01-31
JP5698890B2 (ja) 2015-04-08
CN1845754A (zh) 2006-10-11
US20110059128A1 (en) 2011-03-10
PT2050463E (pt) 2013-10-29
CA2530797C (en) 2014-08-26
ES2356396T3 (es) 2011-04-07
ATE442857T1 (de) 2009-10-15
WO2005002618A1 (en) 2005-01-13
NZ544453A (en) 2009-04-30
CA2530797A1 (en) 2005-01-13
EP2050463A2 (en) 2009-04-22
DE602004023196D1 (de) 2009-10-29
KR20060106809A (ko) 2006-10-12
AU2004253344A1 (en) 2005-01-13
ZA200600918B (en) 2007-07-25
EP1638599A1 (en) 2006-03-29
AU2004253344B2 (en) 2010-04-29
EP2050463B1 (en) 2013-08-21
EP2050463A3 (en) 2010-01-20
GB0315323D0 (en) 2003-08-06
US8329194B2 (en) 2012-12-11
ES2432175T3 (es) 2013-12-02
US20080220018A1 (en) 2008-09-11
JP2007526884A (ja) 2007-09-20
MXPA06000278A (es) 2006-04-07
EP1638599B1 (en) 2009-09-16
US20070098739A1 (en) 2007-05-03
DK2050463T3 (da) 2013-09-02
RU2006102863A (ru) 2006-09-10

Similar Documents

Publication Publication Date Title
Nisbet et al. Successful immunization against a parasitic nematode by vaccination with recombinant proteins
Matthews et al. Progress in the development of subunit vaccines for gastrointestinal nematodes of ruminants
Mohebali et al. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, IR Iran
Cox et al. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines
AR072378A1 (es) Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos.
PA8549701A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
NO20056207L (no) Sammensetning for vaksinering av hunder
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
Bielefeldt-Ohmann et al. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
Jas et al. Three-year duration of immunity for feline herpesvirus and calicivirus evaluated in a controlled vaccination-challenge laboratory trial
Jayashi et al. Characterisation of antibody responses in pigs induced by recombinant oncosphere antigens from Taenia solium
Khalil et al. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major+ BCG) in children: an extended phase II study
Yakobson et al. Cattle rabies vaccination—a longitudinal study of rabies antibody titres in an Israeli dairy herd
BR112021020777A2 (pt) Vacina de subunidade do csfv
Malerczyk et al. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine
Sedgmen et al. Alternative routes of mucosal immunization in large animals
BR0110278A (pt) Composição de vacina, anticorpo ou anti-soro, métodos de produção de um anticorpo ou de um anti-soro e de imunização de um animal contra um ectoparasita que se alimenta de sangue, proteìna de cemento de carrapato, e, uso de uma proteìna de cemento de carrapato
Pecora et al. Development of an enhanced bovine viral diarrhea virus subunit vaccine based on E2 glycoprotein fused to a single chain antibody which targets to antigen-presenting cells
Cabasso et al. Further Evidence of Immunologic Dissimilarity of Distemper (CD) and Measles (M) Viruses.
CN110507819B (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
BRPI0900961B8 (pt) métodos e kit para diagnóstico de leishmaniose
Rashed et al. Mini review on potency evaluation of rabies vaccine preparations
Konstantinov et al. ANTIGENIC AND PROTECTIVE PROPERTIES OF ASSOCIATED VIRUS VACCINE AGAINST SHEEP POX, GOAT POX AND PESTE DES PETITS RUMINANTS
Çokçalışkan et al. Booster administration can make a difference in the antibody response to intradermal foot-and-mouth disease vaccination in cattle

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]